Want to see HK:1530 full AI Analyst Report?
Top Page
3SBio
(1530)
Select Model
Select Model
Rating:78Outperform
Price Target:
HK$17.50
▲(3.18% Upside)
Action:Upgraded
Date:08/22/26
The score is primarily driven by very strong financial performance (sharp 2025 profitability and cash flow improvement, plus lower leverage) and highly attractive valuation (low P/E). Offsetting these positives, technical indicators are only neutral-to-weak, with the stock still below longer-term moving averages and slightly negative MACD, limiting the overall score.
Positive Factors
Accelerating Revenue
The sharp 2025 revenue acceleration indicates substantially stronger commercial performance and product demand. If maintained, this larger revenue base can improve operating leverage, support investment in the pipeline, and strengthen 3SBio’s position across its biopharmaceutical markets.
Negative Factors
Earnings Sustainability Risk
The large 2025 improvement is encouraging, but the uneven record beforehand makes it harder to establish a durable earnings trend. Continued volatility could complicate planning, reduce confidence in normalized profitability, and limit the visibility of medium-term operating performance.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating Revenue
The sharp 2025 revenue acceleration indicates substantially stronger commercial performance and product demand. If maintained, this larger revenue base can improve operating leverage, support investment in the pipeline, and strengthen 3SBio’s position across its biopharmaceutical markets.
Read all positive factors
3SBio (1530) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$40.99B
Dividend Yield1.61%
Average Volume (3M)23.93M
Price to Earnings (P/E)4.0
Beta (1Y)0.85
Revenue Growth101.73%
EPS Growth249.15%
CountryHK
Employees6,068
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)3.44
Shares Outstanding2,538,264,400
10 Day Avg. Volume20,375,977
30 Day Avg. Volume23,933,208
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.97
Price to Sales (P/S)3.03
P/FCF Ratio5.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$28.71Price Target Upside69.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)0.98
Revenue Forecast (FY)HK$9.35B
3SBio Business Overview & Revenue Model
Company Description
Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse port...
How the Company Makes Money
3SBio makes money primarily by selling pharmaceutical and biopharmaceutical products. Its core revenue stream is product sales to hospitals, pharmacies, and other healthcare channels, where revenue is recognized from the commercial distribution of...
3SBio Financial Statement Overview
Summary
Income Statement
92
Very Positive
Balance Sheet
84
Very Positive
Cash Flow
88
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.70B | 9.11B | 7.82B | 6.86B | 6.38B |
| Gross Profit | 16.35B | 7.83B | 6.64B | 5.67B | 5.28B |
| EBITDA | 11.00B | 2.93B | 2.53B | 2.75B | 2.26B |
| Net Income | 8.48B | 2.09B | 1.55B | 1.92B | 1.65B |
Balance Sheet | |||||
| Total Assets | 36.27B | 24.21B | 23.63B | 21.99B | 19.21B |
| Cash, Cash Equivalents and Short-Term Investments | 19.73B | 5.79B | 5.99B | 7.01B | 4.70B |
| Total Debt | 2.62B | 3.55B | 4.84B | 4.52B | 2.63B |
| Total Liabilities | 5.82B | 6.18B | 7.11B | 6.59B | 4.55B |
| Stockholders Equity | 27.22B | 15.44B | 14.03B | 12.96B | 12.23B |
Cash Flow | |||||
| Free Cash Flow | 9.13B | 2.24B | 1.38B | 1.21B | 432.57M |
| Operating Cash Flow | 9.67B | 3.20B | 2.08B | 2.18B | 1.58B |
| Investing Cash Flow | -1.83B | -1.36B | -1.35B | -3.72B | -1.29B |
| Financing Cash Flow | 2.35B | -2.25B | -352.98M | 763.22M | -481.12M |
3SBio Technical Analysis
Negative
16.96
Price Trends
17.21
Negative
18.10
Negative
21.46
Negative
Market Momentum
-0.32
Positive
42.17
Neutral
28.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1530, the sentiment is Negative. The current price of 16.96 is above the 20-day moving average (MA) of 16.86, below the 50-day MA of 17.21, and below the 200-day MA of 21.46, indicating a bearish trend. The MACD of -0.32 indicates Positive momentum. The RSI at 42.17 is Neutral, neither overbought nor oversold. The STOCH value of 28.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1530.
3SBio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$40.99B | 4.01 | 30.16% | 1.61% | 101.73% | 249.15% | |
74 Outperform | HK$202.98B | 33.60 | 10.51% | ― | 21.93% | 21.94% | |
72 Outperform | HK$64.74B | 10.98 | 128.12% | ― | 305.94% | ― | |
64 Neutral | HK$36.64B | 34.72 | 20.41% | ― | 32.63% | 8.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$87.55B | -77.03 | -10.86% | ― | 42.47% | -15.80% | |
46 Neutral | HK$33.50B | -73.86 | -7.32% | ― | 34.83% | 58.94% |
* Healthcare Sector Average
HK:1530
3SBio
15.54
-15.95
-50.66%
HK:2269
Wuxi Biologics (Cayman)
47.50
11.50
31.94%
HK:9926
Akeso, Inc.
93.60
-34.10
-26.70%
HK:9995
RemeGen Co. Ltd. Class H
74.40
-37.30
-33.39%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
17.14
-16.44
-48.96%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
64.50
-14.95
-18.82%
3SBio Corporate Events
3SBio Delivers Modest Revenue Growth but Lower Headline Profit in First Half 2026
Aug 20, 2026
Biopharmaceutical group 3SBio reported interim revenue of RMB4.53 billion for the six months ended 30 June 2026, a 3.9% year-on-year increase, with gross profit up 2.1% to RMB3.79 billion despite a lower gross margin of 83.8%. Net profit attributa...
3SBio Board to Review 2026 Interim Results and Consider Dividend
Aug 7, 2026
3SBio Inc. has announced that its board of directors will convene on 20 August 2026 to review and approve the unaudited interim results for the six months ended 30 June 2026. The meeting will also consider the publication of these results, signall...
3SBio Shareholders Approve Dividend and Auditor Change at AGM
Jun 25, 2026
Shareholders of 3SBio Inc. approved all resolutions at the annual general meeting held on 25 June 2026, including the adoption of the 2025 audited financial statements and the re-election of two independent non-executive directors. Voting was cond...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.